Avalo Therapeutics News and Activities

Avalo Therapeutics is a company listed under the stock ticker AVTX (US).

Acquisition, funding and merger involving Avalo Therapeutics.

• Avalo Therapeutics has just announced a $375 Million fundraising (posted on May 6 2026).

View the org chart displaying its 25 main executives

Most searched biographies at Avalo Therapeutics

• Garry Neil, Chief Executive Officer
• Mitchell Chan, Director
• Kevin Lind, Director

Popular executive movements at Avalo Therapeutics

• Ashley Ivanowicz has joined the company as Senior Vice President, Human Resources  (posted on October 1 2025).
• Taylor Boyd has joined the company as Chief Business Officer  (posted on October 1 2025).
• Kevin Lind has joined the company as Director  (posted on September 23 2025).

Create your alert
to follow the executive moves at Avalo Therapeutics.

Avalo Therapeutics has 2,406 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Patrick Enright - Director at CuraSen Therapeutics

Learn more about the Biotechnology industry

Press releases by Avalo Therapeutics

• Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer :: Avalo Therapeutics, Inc. (AVTX)
• Avalo Therapeutics to Present at Upcoming Investor Conferences :: Avalo Therapeutics, Inc. (AVTX)
• Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants :: Avalo Therapeutics, Inc. (AVTX)
• Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates :: Avalo Therapeutics, Inc. (AVTX)
• Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa :: Avalo Therapeutics, Inc. (AVTX)
• Avalo Announces Participation in September Investor Conferences :: Avalo Therapeutics, Inc. (AVTX)
• Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer :: Avalo Therapeutics, Inc. (AVTX)
• Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates :: Avalo Therapeutics, Inc. (AVTX)
• Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa :: Avalo Therapeutics, Inc. (AVTX)
• Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit :: Avalo Therapeutics, Inc. (AVTX)
• View more press releases Close

Social media about Avalo Therapeutics

• Avalo Therapeutics on Wikipedia, Google News & Yahoo Finance
• Avalo Therapeutics on LinkedIn, X (Twitter) & YouTube